Exact Mass: 521.3175
Exact Mass Matches: 521.3175
Found 500 metabolites which its exact mass value is equals to given mass value 521.3175,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
LysoPC (18:1/0:0)
LysoPC(18:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:19Z)), in particular, consists of one chain of oleic acid at the C-1 position. The oleic acid moiety, an omega-9 fatty acid, is derived from various animal and vegetable sources such as olive oil, acai and grapeseed oil. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. Lysophosphatidylcholines (LPC), also called lysolecithins, are a class of chemical compounds which are derived from phosphatidylcholines. They result from partial hydrolysis of phosphatidylcholines, which removes one of the fatty acid groups. The hydrolysis is generally the result of the enzymatic action of phospholipase A2. LPC is present as a minor phospholipid in the cell membrane (<=3\\%) and in the blood plasma (8-12\\%). Since LPCs are quickly metabolized by lysophosholypase and LPC-acyltransferase, they last only shortly in vivo. [Wikipedia]. Lysolecithin is found in many foods, some of which are cardamom, cucumber, common buckwheat, and rice.
LysoPC(18:1(11Z)/0:0)
LysoPC(18:1(11Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:1(11Z)), in particular, consists of one chain of vaccenic acid at the C-1 position. The vaccenic acid moiety is derived from butter fat and animal fat. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(18:1(11Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:1(11Z)), in particular, consists of one chain of vaccenic acid at the C-1 position. The vaccenic acid moiety is derived from butter fat and animal fat. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
LysoPC(0:0/18:1(9Z))
LysoPC(0:0/18:1(9Z)) is a lysophosphatidylcholine, which is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2 as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. There is also a phospholipase A1, which is able to cleave the sn-1 ester bond. Lysophosphatidylcholine has pro-inflammatory properties in vitro and it is known to be a pathological component of oxidized lipoproteins (LDL) in plasma and of atherosclerotic lesions. Recently, it has been found to have some functions in cell signalling, and specific receptors (coupled to G proteins) have been identified. It activates the specific phospholipase C that releases diacylglycerols and inositol triphosphate with resultant increases in intracellular Ca2+ and activation of protein kinase C. It also activates the mitogen-activated protein kinase in certain cell types. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPC(0:0/18:1(9Z)), in particular, consists of one chain of oleic acid at the C-2 position.
Chenodeoxycholylglutamic acid
Chenodeoxycholylglutamic acid belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylglutamic acid consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Glutamic acid conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylglutamic acid, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylglutamic acid appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylglutamic acid
Deoxycholylglutamic acid belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylglutamic acid consists of the bile acid deoxycholic acid conjugated to the amino acid Glutamic acid conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylglutamic acid, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylglutamic acid appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
2-[2-(17-Amino-5,13,14,16-tetrahydroxy-3,7-dimethylheptadecan-4-yl)oxy-2-oxoethyl]butanedioic acid
Thr Phe Val Arg
Ile Val Tyr Lys
Phe Lys Val Glu
(1S,4R,5R,6S,8R,10R,13S,16S,18R)-4-(acetyloxy)-11-ethyl-16-hydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate
LPC 18:1
Annotation level-3
Lyso-PC 18:1(9Z)
This mass spectral data is shown in Figure S7 of the publication.; Figure S7 shows that O attached precursor ions, [M+H+O*]+, are predominantly in the epoxide form. The [M+H+O*]+ ion is the product that [M+H]+ reacts with H2O microwave discharge (MSJ00187). The products of microwave discharge are mixture of gas-phase H*, OH*, and 3O (triplet O) radicals.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of HAD, and TOF analyzes the product ions.; MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). FRAGMENTATION_MODE is RID that is Radical Induced Dissociation; MALDI generates [M+H]+ ion, which is dissociated by the reaction with 3O (triplet O) generated by O2 microwave discharge.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data and fragment ions produced are shown in Figure S6_2 of the publication.; Relative intensity of the peaks m/z 180-199 is magnified by x5, those of the peaks m/z 200-507 by 100.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). MSJ00188 is shown in Figure 5 of the publication. The precursor ion is the [M+H+O]+ ion that is a major product ion of the reaction product of [M+H]+ with H2O microwave discharge (MSJ00187). In the present experiment, [M+H+O]+ ions are induced by the injection of 3O (triplet) from the microwave discharge of pure O2 gas.; Figure 5 shows that O attached precursor ions, [M+H+O]+, are predominantly in the epoxide form.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of HAD, and TOF analyzes the product ions.; MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). MALDI generates a stable [M+H]+ ion. [M+H]+ reacts with the mixture of OH* and H* radicals, and 3O (triplet O) atom that microwave discharge of H2O generates. The reaction products, consisting of [M+H+H*], [M+H+O]+ and [M+H+OH*]+ ions, are dissociated to give product ions, which are detected as RID product ions.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data is shown in Figure S5 of the publication. Fragment ions produced are explained in Scheme 2 of the publication. MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; Relative Intensity of the peaks is magnified; m/z 180-199 by x5, m/z 200-505 by x100; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). MALDI generates a stable [M+H]+ ion. Microwave discharge of H2O generates OH*, H* and 3O (triplet O) radicals. These radicals react with the stable [M+H]+ ion and give a mixture of [M+H+H*], [M+H+O]+ and [M+H+OH*]+ ions. In the present experiment, O2 gas is introduced after the H2O discharge.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data is shown in Figure 4(C) of the publication. Fragment ions produced are annotated in Scheme 2 of the publication. MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; Relative intensity of the peaks from m/z 300 to 499 is magnified by x10.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). RID is Radical Induced Dissociation; MALDI generates [M+H]+ ion, which is dissociated by the reaction with 3O (triplet O) generated by O2 microwave discharge.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data is shown in Figure 4(B) of the publication. Fragment ions produced are annotated in Scheme 2. MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; Relative Intensity of the peaks from m/z 300 to 499 is magnified by x10.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). What is Radical Induced Dissociation (RID)? Microwave discharge of H2O generates OH*, H* and 3O (triplet O) radicals. These radicals react to dissociate the stable [M+H]+ ion.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data is shown in Figure 4(A) of the publication. Fragment ions produced are annotated in Scheme 2. MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; Relative intensity of the peaks from m/z 300 to 499 is magnified by x100.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). This is an experiment to compare with MSJ00179 that uses Hydrogen Abstraction Dissociation (HAD) instead of CID for the dissociation of [M+H]+.; This mass spectral data is shown in Figure S3 of the publication.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of HAD, and TOF analyzes the product ions.; MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; The sample was injected by direct infusion.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). FRAGMENTATION_MODE is HAD that is Hydrogen Abstraction Dissociation; MALDI generates [M+H]+ ion, which is dissociated by the reaction with hydrogen radical (H*) generated by microwave-driven radical generator.; This mass spectral data is shown in Figure 1(A) of the publication.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of HAD, and TOF analyzes the product ions.; MS data of the substance is MSJ00178; Figure 1(A) Inset in the publication.; The sample was injected by direct infusion.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). This mass spectral data is shown in Figure 1(A) Inset of the publication.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL).
(1S,4R,5R,6S,8R,10R,13S,16S,18R)-4-(acetyloxy)-11-ethyl-16-hydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate_major
Ala Ile Arg Tyr
Ala Ile Tyr Arg
Ala Leu Arg Tyr
Ala Leu Tyr Arg
Ala Arg Ile Tyr
Ala Arg Leu Tyr
Ala Arg Tyr Ile
Ala Arg Tyr Leu
Ala Tyr Ile Arg
Ala Tyr Leu Arg
Ala Tyr Arg Ile
Ala Tyr Arg Leu
Asp Phe Ile Lys
Asp Phe Lys Ile
Asp Phe Lys Leu
Asp Phe Leu Lys
Asp Ile Phe Lys
Asp Ile Lys Phe
Asp Lys Phe Ile
Asp Lys Phe Leu
Asp Lys Ile Phe
Asp Lys Leu Phe
Asp Leu Phe Lys
Asp Leu Lys Phe
Glu Phe Lys Val
Glu Phe Val Lys
Glu Lys Phe Val
Glu Lys Val Phe
Glu Val Phe Lys
Glu Val Lys Phe
Phe Asp Ile Lys
Phe Asp Lys Ile
Phe Asp Lys Leu
Phe Asp Leu Lys
Phe Glu Lys Val
Phe Glu Val Lys
Phe Ile Asp Lys
Phe Ile Lys Asp
Phe Ile Arg Ser
Phe Ile Ser Arg
Phe Lys Asp Ile
Phe Lys Asp Leu
Phe Lys Glu Val
Phe Lys Ile Asp
Phe Lys Leu Asp
Phe Leu Asp Lys
Phe Leu Lys Asp
Phe Leu Arg Ser
Phe Leu Ser Arg
Phe Arg Ile Ser
Phe Arg Leu Ser
Phe Arg Ser Ile
Phe Arg Ser Leu
Phe Arg Thr Val
Phe Arg Val Thr
Phe Ser Ile Arg
Phe Ser Leu Arg
Phe Ser Arg Ile
Phe Ser Arg Leu
Phe Thr Arg Val
Phe Thr Val Arg
Phe Val Glu Lys
Phe Val Lys Glu
Phe Val Arg Thr
Phe Val Thr Arg
His Ile Pro Arg
His Ile Arg Pro
His Leu Pro Arg
His Leu Arg Pro
His Pro Ile Arg
His Pro Leu Arg
His Pro Arg Ile
His Pro Arg Leu
His Arg Ile Pro
His Arg Leu Pro
His Arg Pro Ile
His Arg Pro Leu
Ile Ala Arg Tyr
Ile Ala Tyr Arg
Ile Asp Phe Lys
Ile Asp Lys Phe
Ile Phe Asp Lys
Ile Phe Lys Asp
Ile Phe Arg Ser
Ile Phe Ser Arg
Ile His Pro Arg
Ile His Arg Pro
Ile Ile Asn Tyr
Ile Ile Tyr Asn
Ile Lys Asp Phe
Ile Lys Phe Asp
Ile Lys Val Tyr
Ile Lys Tyr Val
Ile Leu Asn Tyr
Ile Leu Tyr Asn
Ile Asn Ile Tyr
Ile Asn Leu Tyr
Ile Asn Tyr Ile
Ile Asn Tyr Leu
Ile Pro His Arg
Ile Pro Arg His
Ile Gln Val Tyr
Ile Gln Tyr Val
Ile Arg Ala Tyr
Ile Arg Phe Ser
Ile Arg His Pro
Ile Arg Pro His
Ile Arg Ser Phe
Ile Arg Tyr Ala
Ile Ser Phe Arg
Ile Ser Arg Phe
Ile Val Lys Tyr
Ile Val Gln Tyr
Ile Val Tyr Gln
Ile Tyr Ala Arg
Ile Tyr Ile Asn
Ile Tyr Lys Val
Ile Tyr Leu Asn
Ile Tyr Asn Ile
Ile Tyr Asn Leu
Ile Tyr Gln Val
Ile Tyr Arg Ala
Ile Tyr Val Lys
Ile Tyr Val Gln
Lys Asp Phe Ile
Lys Asp Phe Leu
Lys Asp Ile Phe
Lys Asp Leu Phe
Lys Glu Phe Val
Lys Glu Val Phe
Lys Phe Asp Ile
Lys Phe Asp Leu
Lys Phe Glu Val
Lys Phe Ile Asp
Lys Phe Leu Asp
Lys Phe Val Glu
Lys Ile Asp Phe
Lys Ile Phe Asp
Lys Ile Val Tyr
Lys Ile Tyr Val
Lys Leu Asp Phe
Lys Leu Phe Asp
Lys Leu Val Tyr
Lys Leu Tyr Val
Lys Val Glu Phe
Lys Val Phe Glu
Lys Val Ile Tyr
Lys Val Leu Tyr
Lys Val Tyr Ile
Lys Val Tyr Leu
Lys Tyr Ile Val
Lys Tyr Leu Val
Lys Tyr Val Ile
Lys Tyr Val Leu
Leu Ala Arg Tyr
Leu Ala Tyr Arg
Leu Asp Phe Lys
Leu Asp Lys Phe
Leu Phe Asp Lys
Leu Phe Lys Asp
Leu Phe Arg Ser
Leu Phe Ser Arg
Leu His Pro Arg
Leu His Arg Pro
Leu Ile Asn Tyr
Leu Ile Tyr Asn
Leu Lys Asp Phe
Leu Lys Phe Asp
Leu Lys Val Tyr
Leu Lys Tyr Val
Leu Leu Asn Tyr
Leu Leu Tyr Asn
Leu Pro His Arg
Leu Pro Arg His
Leu Arg Ala Tyr
Leu Arg Phe Ser
Leu Arg His Pro
Leu Arg Pro His
Leu Arg Ser Phe
Leu Arg Tyr Ala
Leu Ser Phe Arg
Leu Ser Arg Phe
Leu Val Lys Tyr
Leu Val Tyr Lys
Leu Tyr Ala Arg
Leu Tyr Lys Val
Leu Tyr Arg Ala
Leu Tyr Val Lys
Pro His Ile Arg
Pro His Leu Arg
Pro His Arg Ile
Pro His Arg Leu
Pro Ile His Arg
Pro Ile Arg His
Pro Leu His Arg
Pro Leu Arg His
Pro Arg His Ile
Pro Arg His Leu
Pro Arg Ile His
Pro Arg Leu His
Arg Ala Ile Tyr
Arg Ala Leu Tyr
Arg Ala Tyr Ile
Arg Ala Tyr Leu
Arg Phe Ile Ser
Arg Phe Leu Ser
Arg Phe Ser Ile
Arg Phe Ser Leu
Arg Phe Thr Val
Arg Phe Val Thr
Arg His Ile Pro
Arg His Leu Pro
Arg His Pro Ile
Arg His Pro Leu
Arg Ile Ala Tyr
Arg Ile Phe Ser
Arg Ile His Pro
Arg Ile Pro His
Arg Ile Ser Phe
Arg Ile Tyr Ala
Arg Leu Ala Tyr
Arg Leu Phe Ser
Arg Leu His Pro
Arg Leu Pro His
Arg Leu Ser Phe
Arg Leu Tyr Ala
Arg Pro His Ile
Arg Pro His Leu
Arg Pro Ile His
Arg Pro Leu His
Arg Ser Phe Ile
Arg Ser Phe Leu
Arg Ser Ile Phe
Arg Ser Leu Phe
Arg Thr Phe Val
Arg Thr Val Phe
Arg Val Phe Thr
Arg Val Thr Phe
Arg Tyr Ala Ile
Arg Tyr Ala Leu
Arg Tyr Ile Ala
Arg Tyr Leu Ala
Ser Phe Ile Arg
Ser Phe Leu Arg
Ser Phe Arg Ile
Ser Phe Arg Leu
Ser Ile Phe Arg
Ser Ile Arg Phe
Ser Leu Phe Arg
Ser Leu Arg Phe
Ser Arg Phe Ile
Ser Arg Phe Leu
Ser Arg Ile Phe
Ser Arg Leu Phe
Thr Phe Arg Val
Thr Arg Phe Val
Thr Arg Val Phe
Thr Val Phe Arg
Thr Val Arg Phe
Val Phe Arg Thr
Val Phe Thr Arg
Val Ile Lys Tyr
Val Ile Tyr Lys
Val Lys Ile Tyr
Val Lys Leu Tyr
Val Lys Tyr Ile
Val Lys Tyr Leu
Val Leu Lys Tyr
Val Leu Tyr Lys
Val Arg Phe Thr
Val Arg Thr Phe
Val Thr Phe Arg
Val Thr Arg Phe
Val Tyr Ile Lys
Val Tyr Lys Ile
Val Tyr Lys Leu
Val Tyr Leu Lys
Tyr Ala Ile Arg
Tyr Ala Leu Arg
Tyr Ala Arg Ile
Tyr Ala Arg Leu
Tyr Ile Ala Arg
Tyr Ile Lys Val
Tyr Ile Arg Ala
Tyr Ile Val Lys
Tyr Lys Ile Val
Tyr Lys Leu Val
Tyr Lys Val Ile
Tyr Lys Val Leu
Tyr Leu Ala Arg
Tyr Leu Lys Val
Tyr Leu Arg Ala
Tyr Leu Val Lys
Tyr Arg Ala Ile
Tyr Arg Ala Leu
Tyr Arg Ile Ala
Tyr Arg Leu Ala
Tyr Val Ile Lys
Tyr Val Lys Ile
Tyr Val Lys Leu
Tyr Val Leu Lys
Platelet-activating factor
PC(P-16:0/2:0)
PC(18:1/0:0)
PC(18:1/0:0)[U]
PC(0:0/18:1)
Elaidin, 2-mono-,
PC(0:0/18:1)[U]
4-[(9-cyclopentyl-5,8-dimethyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide
14-(Acetyloxy)-20-ethyl-1-hydroxy-6,16-dimethoxy-4-(methoxymethyl)aconitan-8-yl acetate
1-Elaidoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:1 in which the acyl group is at position 1 is elaidoyl [(9E)-octadec-9-enoyl] and the hydoxy group at position 2 is unsubstituted.
(1S,2R,5S,7S,12S,15S)-1,2-dimethyl-7-[2-(3-methylbut-2-enoxy)propan-2-yl]-6,10-dioxa-24-azaheptacyclo[13.10.0.02,12.05,11.09,11.017,25.018,23]pentacosa-17(25),18,20,22-tetraene-8,12-diol
2-C22:0-alpha,omega-dicaboxyl-lysophosphatidic acid
[2-hydroxy-3-[(E)-octadec-6-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(2R)-2-(acetyloxy)-3-{[(9Z)-hexadec-9-en-1-yl]oxy}propyl 2-(trimethylazaniumyl)ethyl phosphate
[2-hydroxy-3-[(E)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
propan-2-yl N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
propan-2-yl N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
propan-2-yl N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
[2-acetyloxy-3-[(Z)-hexadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2S)-3-hydroxy-2-[(Z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(Z)-16,16,17,17,18,18,18-heptadeuteriooctadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-henicos-11-enoate
[2-pentanoyloxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] octanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] hexanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] (Z)-tridec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] acetate
[3-[(Z)-pentadec-9-enoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]undec-4-ene-1-sulfonic acid
(4E,8E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxytrideca-4,8-diene-1-sulfonic acid
4-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-propanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] heptanoate
[2-butanoyloxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] pentanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] propanoate
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-octadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (Z)-tetradec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (Z)-tridec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-heptadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (Z)-hexadec-9-enoate
[3-acetyloxy-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-butanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-propanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(1S,4R,5R,6S,8R,10R,13S,16S,17R,18R)-8-acetyloxy-11-ethyl-16-hydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] acetate
[(2R)-2-hydroxy-3-[(E)-octadec-6-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-[(E)-octadec-4-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-octadec-17-enoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-[(E)-octadec-11-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-[(E)-octadec-13-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-[(E)-octadec-7-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
Terpendole J
An organic heteroheptacyclic compound isolated from Albophoma yamanashiensis and has been shown to exhibit inhibitory activity against acyl-CoA:cholesterol acyltransferase.
2-Oleoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:1 in which the acyl group is specified as oleoyl and is located at position 2.
Lysophosphatidylcholine 18:1
A lysophosphatidylcholine in which the remaining acyl group (position not specified) contains 18 carbons with 1 double bond.
1-O-Oleoyl-sn-glycero-3-phosphocholine
An oleoyl-sn-glycero-3-phosphocholine in which the acyl group at position 1 is (9Z)-octadecenoyl (oleoyl) and the hydroxy group at position 2 is unsubstituted. A lysophosphatidylcholine 18:1 in which the acyl group at position 1 is (9Z)-octadecenoyl and the hydroxy group at position 2 is unsubstituted.
lysophosphatidylcholine (18:1/0:0)
A lysophosphatidylcholine 18:1 in which the acyl group is located at position 1.
lysophosphatidylcholine (0:0/18:1)
A lysophosphatidylcholine 18:1 in which the acyl group is located at position 2.
oleoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:1 in which the acyl group is specified as oleoyl and is located at either position 1 or 2.
1-[(9Z)-hexadecenyl]-2-acetyl-sn-glycero-3-phosphocholine
A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as (9Z)-hexadecenyl.
1-[(11Z)-octadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:1 in which the acyl group specified as position 1 is (11Z)-octadecenoyl.
MePC(17:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(17:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
